ABSTRACT The bioactivity of 10-formyl-7,8-dihydrofolic acid and 10-formyl-folic acid was determined in human leukemia (CCRF-CEM) cells grown in a folate-depleted medium containing methotrexate. Excess 10-formyl-7,8-dihydrofolic acid, (but not 10-formyl folic acid) supported the growth of these cells, but it was less potent than 5-formyl-5,6,7,8-tetrahydrofolic acid (a control). 10-formyl-7,8-dihydrofolic acid (not 10-formyl folic acid) was active as substrate for aminoimidazole carboxamide ribotide transformylase and dihydrofolate reductase. This is the first experimental evidence that 10-formyl-7,8-dihydrofolic acid is a bioactive folate in mammalian cells. These experiments and several other lines of evidence in the literature suggest that 10-formyl-folic acid must be metabolized to bioactive folate by enteric bacteria before it can be utilized by the vertebrate host. J. Nutr. 129: 1315-1318, 1999.
The pteridine ring of folates can exist at three levels of oxidation: 5, 6, 7, 8 tetrahydro, 7, 8 or 5, 6 dihydro, and fully oxidized state (e.g. folic acid). Folates having a one-carbon substituent at the formyl oxidation state occur in nature as 5-formyl-, 5-formimino-, 5, 10-methenyl-or 10-formyl-5,6,7,8 tetrahydrofolic acid; 10-formyl-7,8 dihydrofolic acid; and 10-formyl-folic acid (Temple and Montgomery, 1984) . Using chromatography followed by differential microbiological assay, Butterworth et al. (1963) identified both 5-formyl-tetrahydrofolic acid and 10-formyl-folic acid in mixed diets. Recently, using HPLC, Pfeiffer et al. (1997) have identified 5-formyltetrahydrofolic acid, 10-formyl-folic acid, and 10-formyl-dihydrofolic acid in cereal-grain food products.
All of the above substances support the growth of the folate-requiring bacteria L. casei and E. hirae (formerly S. faecalis) Rabinowitz 1960 ). Because the above bacteria must readily metabolize these folates, it was assumed that mammalian cells would have similar metabolic pathways available. The bioactivities of 5-formyl-5,6,7,8-tetrahydrofolic acid (5-HCO-H 4 folic acid), 2 as a control, 10-formyl-7,8,-dihydrofolic acid (10-HCO-H 2 folic acid); and 10-formyl-folic acid (10-HCO-folic acid) were determined in mammalian cells in a bacteria-free environment. We report here that excess 10-HCO-H 2 folic acid, but not 10-HCO-folic acid, supports the growth of human leukemia cells (CCRF-CEM cells) grown in a culture medium containing methotrexate (MTX).
MATERIALS AND METHODS
Materials. Sources and preparation of aminoimidazole carboxamide ribotide (AICAR) (6S) 5-HCO-H 4 folic acid and (6R) 10-formyl-5,6,7,8 tetrahydrofolic acid (10-HCO-H 4 folic acid) were described previously (Baggott et al. 1995) . NADPH and ascorbic acid were purchased from Sigma Chemical (St. Louis, MO). 10-HCO-H 2 folic acid was prepared by air oxidation of (6R) 10-HCO-H 4 folic acid as previously described (Baggott et al. 1995) . 10-HCO-folic acid was prepared by dissolving folic acid in 98% formic acid for several days and recrystallized from hot water until a constant UV spectrum was obtained. Stock solutions of the above folates were made 0.5 to 1 ϫ 10 -3 mol/L in 0.01 mol/L Tris buffer, pH 8.0. The UV spectra of 10-HCO-folic acid and 10-HCO-H 2 folic acid are shown in Figure  1A and B, respectively.
Concentrations of folates were estimated using the following molar extinction coefficients (⑀ in L/mol ϫ cm), at pH 7.0: folic acid, ⑀ 282 ϭ 2.7 ϫ 10 4 ; 10-HCO-folic acid, ⑀ 271 ϭ 2.7 ϫ 10 4 ; 10-HCO-H 2 folic acid, ⑀ 234 ϭ 3.4 ϫ 10 4 ; 5-HCO-H 4 folic acid, ⑀ 287 ϭ 3.2 ϫ 10 4 ; and at pH 1.0: 10-HCO-H 4 folic acid as 5,10-CH ϭ H 4 folic acid, ⑀ 356 ϭ 2.5 ϫ 10 4 (Baggott et al. 1995 , Rabinowitz 1960 , Temple and Montgomery 1984 . The neutral pH UV spectrum of 10-HCOfolic acid is shown in Rabinowitz (1960) as having ( max) ⑀ 270 ϭ 2.1 ϫ 10 4 , but is reported by Temple and Montgomery (1984) as having ( inflection point) ⑀ 263 ϭ 2.6 ϫ 10 4 . Thus our molar extinction coefficient for 10-HCO-folic acid at 271 nm agrees better with that reported by the latter investigators. To ensure that no 10-HCO-H 4 folic acid remained in the preparation of 10-HCO-H 2 folic acid, the latter was over-oxidized, which changed its UV spectra as shown in Figure 1C .
Cell culture experiments. The human acute lymphoblastic leukemia cell line CCRF-CEM was obtained from the American Type Culture Collection (Rockville, MD; ATCC # CCL 119). Cells were routinely grown at 37°C in a humidified atmosphere of 5% CO 2 in RPMI medium 1640 (without added folic acid) (Gibco BRL, Gaithersburg, MD), 20% dialyzed fetal bovine serum (HyClone Laboratories, Logan, UT), and an antibiotic mixture of 1.0 ϫ 10 5 IU penicillin/L, 100 mg streptomycin/L, and 0.25 mg fungizone/L (Irvine Scientific, Santa Ana, CA). Folates were added in the concentrations indicated in Table 1 at the beginning of the cell culture experiments. The experiments were conducted in 24-well plates seeded with 1 ϫ 10 8 cells/L. At the end of the culture period, volumes were measured, and cell counts were performed using an automated cell counter (Coulter, model ZM, Luton Beds, U.K.). An average of Ն5 cell count deter-minations was used. The percentage viability was determined by trypan blue exclusion. An average of Ն4 microscope fields was used to determine percentage viability.
Enzyme assays. A previously described colorimetric assay (the change in absorbance at 552 nm, ⌬A 552 ) of AICAR Transformylase (AICAR Tase) was performed by using initial concentrations of 5 ϫ 10 -4 mol AICAR/L, 5 ϫ 10 -4 mol of the folate/L, 1 ϫ 10 -3 mol ascorbate/L, and 0.1 mol K phosphate buffer/L (pH 7.0) at 23°C (Baggott et al. 1995) . Each assay contained 1.4 mg protein of CCRF-CEM extract per mL. Blank assays contained all components except the folate.
A spectrophotometric assay of dihydrofolate reductase was performed by using concentrations of 5 ϫ 10 -4 mol NADPH/L, 5 ϫ 10 -4 mol of the folate/L, 1 ϫ 10 -3 mol ascorbate/L, and 0.1 mol K phosphate/L (pH 7.0) at 23°C. Each assay contained 0.8 mg protein of CCRF-CEM extract/mL. Aliquots of the assay solution were diluted 1:10 into the phosphate-ascorbate buffer before measuring the change in absorbance at 340 nm (⌬A 340 ). Blank assays contained all components except the folate.
Extracts of CCRF-CEM cells were made by freezing and thawing, three times, in the above phosphate buffer. The absorbance at 280 nm (A 280 ) was used to measure CCRF-CEM protein concentration; an A 280 ϭ 1 was assumed to be 1 g protein/L.
Statistics. Differences in mean fractional change in cell growth were detected by the t-test. Square root transformations of the data were used to normalize the data.
Differences in mean enzyme activity (⌬A 552 or ⌬A 340 ) at the final assay point (ϳ280 min for ⌬A 340 and 24 h for ⌬A 552 ) were detected by ANOVA followed by Scheffe's test.
RESULTS
Cell culture experiments using three concentrations of MTX and five concentrations of each folate demonstrated that FIGURE 1 The UV spectra (pH 7) of (A) 3.5 x 10 -5 mol 10-formylfolic acid (10-HCO-folic acid)/L: max ϭ 348, 271, and 242 nm; min ϭ 302, 252 nm. (B) 2.7 x 10 -5 mol 10-formyl-5,6,7,8 tetrahydrofolic acid (10-HCO-H 4 folic acid)/L, which was air oxidized to the same concentration of 10-formyl-7,8-dihydrofolic acid (10-HCO-H 2 folic acid): max ϭ 332, 234 nm; min ϭ 302 nm. (C) 3.5 x 10 -5 mol 10-HCO-H 4 folic acid/L, which was air oxidized to the same concentration of 10-HCO-H 2 folic acid, then overoxidized to produce some 10-HCO-folic acid: max ϭ 348, 255 nm, min ϭ 311 nm; however, these values are not for a pure compound. Each well was seeded with 1 ϫ 10 5 viable cells. 2 MTX, methotrexate; 10-HCO-folic acid, 10-formyl-folic acid; 10-HCO-H 2 folic acid, 10-formyl-7,8-dihydrofolic acid; 5-HCO-H 4 folic acid, 5-formyl-5,6,7,8 tetrahydrofolic acid. 3 The number of cells in the control (no added folates) ϭ 1.9 ϫ 10 6 ; percentage viability varied from 98 to 100%. 4 The number of cells in the control (no added folates) ϭ 3.7 ϫ 10 5 ; percentage viability varied from 88 to 97%. 5 The number of cells in the control (no added folates) ϭ 3.8 ϫ 10 5 ; percentage variability varied from 78 to 97%. 6 The number of cells in the control (no added folates) ϭ 7.4 ϫ 10 4 ; percentage viability varied from 31 to 100%. 7 The number of cells in the control (no added folates) ϭ 4.9 ϫ 10 4 .
TABLE 1

Growth of human leukemia cells (CCRF-CEM) in folate depleted media with MTX in the presence of 10-HCO-folic acid, 10-HCO-H 2 folic acid, and 5-HCO-H 4 folic acid.
both 5-HCO-H 4 folic acid and 10-HCO-H 2 folic acid supported the growth of CCRF-CEM cells in the presence of MTX as shown in Table 1 . At the 25 and 100 nmol/L concentrations of MTX, both of these compounds showed a dose dependency in the stimulation of cell growth above control levels and in percentage viability. These folates were also capable of preventing net cell death, which occurred in the controls with the highest concentration of MTX. In contrast, in the vast majority of experiments using 10-HCO-folic acid, there was either no cell growth stimulation above control levels or there was actual cell growth inhibition. Means of fractional change in cell growth were 0.0 and 0.7 using 10-HCO-folic acid and 10-HCO-H 2 folic acid, respectively (P ϭ 0.001). The substrate activity of these folates was assayed by using two folate metabolizing enzymes. Dihydrofolate reductase, from CCRF-CEM cells, readily utilized both 10-HCO-H 2 folic acid and folic acid (a control), but had little or no activity with 10-HCO-folic acid ( Fig. 2A ). All three substrates had different activities (P Ͻ 0.05). AICAR Tase, from CCRF-CEM cells, was active with 10-HCO-H 2 folic acid and 10-HCO-H 4 folic acid (a control), but had little or no activity with 10-HCO-folic acid (Fig. 2B) . Both the tetra and dihydro folates had higher activities than did 10-HCO-folic acid (P Ͻ 0.05).
DISCUSSION
Cell culture growth experiments were selected because they are free of bacterial contamination. Therefore, endogenous or exogenous bacteria will not participate in the metabolism of the folates. The human leukemia cell line, CCRF-CEM, was chosen because it can be grown in culture for relatively long periods of time without appreciable cell death, and its growth is inhibited by nanomolar concentrations of MTX (Haber et al. 1989 and . This latter fact indicates that their growth is dependent upon bioactive folates. We elected to use MTX in the media to minimize the effect of the folates in the seed cells and the folates which cannot be removed from the culture medium. MTX and its polyglutamates are well known inhibitors of many folate-utilizing enzymes, and therefore, MTX treatment will stress cellular folate metabolism and suppress cell growth. This antifolate-induced cell growth suppression can be reversed by adding bioactive folates. A variety of cell culture times and concentrations of the folate and MTX concentrations were used to increase the chances of finding this reversal of antifolate-induced cell growth suppression. To our knowledge, this is the first report of the use of 10-HCO-H 2 folic acid and 10-HCO-folic acid in mammalian cell culture.
The cell culture experiments used 5-HCO-H 4 folic acid as a control and it reversed the effects of MTX. Our cell culture experiments indicate that 10-HCO-H 2 folic acid reverses the antifolate effects of MTX, but was less potent than 5-HCO-H 4 folic acid. The fact that the initial preparation of 10-HCO-H 2 folic acid was overoxidized and contained some 10-HCOfolic acid may partially account for its reduced potency. Some oxidation of 10-HCO-H 2 folic acid to 10-HCO-folic acid must also have occurred during the 4 -6 d of cell culture (Baggott et al. 1995) . We found little or no evidence for 10-HCO-folic acid being a bioactive folate by reversing the effect of antifolate-induced cell growth suppression in this cell line. Although our results apply strictly to human leukemia, it is likely that 10-HCO-folic acid is metabolically inert for normal mammalian and vertebrate cells. Our results are consistent with several other lines of evidence, which are discussed below.
Human experiments indicate that 10-HCO-folate has relatively low bioactivity. In an early report by Spies et al. (1948) , 20 mg/d oral doses of 10-HCO-folic acid for 10 d produced a much weaker reticulocyte response than did 10 mg/d oral doses of folic acid for 10 d in a patient with nutritional macrocytic anemia and in a patient with pernicious anemia. The peak reticulocyte response occurred at 10 -13 d after the initiation of 10-HCO-folic acid therapy versus only 7-8 d after the initiation of folic acid therapy. In a 12-h experiment in humans, 20 -40% of a 5 mg oral dose of radiolabeled 10-HCO-folic acid was excreted, unmetabolized, in the urine. Only ϳ1% of this dose was identified in urine as 5-methyl-tetrahydrofolic acid (5-CH 3 -H 4 folic acid) (Saleh et al. 1982) . Ratanasthien et al. (1974) reported that 10-HCOfolic acid appeared in plasma, unmetabolized, up to 3 h after a 5 mg oral dose. In contrast, 25-30% of the total increase in plasma folates was 5-CH 3 -H 4 folic acid within 3 h after an oral dose of 5 mg of folic acid. Thus, in this short-term experiment, substantial metabolism of folic acid had occurred, whereas 10-HCO-folic acid was not metabolized.
Our enzyme studies also suggest that 10-HCO-folic acid is metabolically inert. CCRF-CEM AICAR Tase utilized both 10-HCO-H 4 folic acid and 10-HCO-H 2 folic acid but not 10-HCO-folic acid which is in agreement with reports using chicken liver AICAR Tase and mammalian AICAR Tase (Baggott et al. 1986 and 1995) . CCRF-CEM dihydrofolate reductase utilized both folic acid and 10-HCO-H 2 folic acid, but not 10-HCO-folic acid. This was expected because 10-HCO-folic acid is known to be an inhibitor of (not a substrate for) mammalian dihydrofolate reductase Whitburn et al. 1983 ). Indeed, 10-HCO-folic acid has very little activity with chicken liver glycinamide ribotide transformylase (Smith et al. 1981) , and the reversible reaction catalyzed by bacterial 10-formyl-tetrahydrofolic acid synthetase does not utilize folic acid, and thus 10-HCO-folic acid cannot be converted to folic acid by this synthetase (Buttlaire 1980) . We are unaware of any mammalian enzyme that effectively metabolizes 10-HCO-folic acid.
FIGURE 2
The assay of (A) CCRF-CEM dihydrofolate reductase (⌬A 340 ) using 10-formyl-folic acid (10-HCO-folic acid), folic acid and 10-formyl-7,8-dihydrofolic acid (10-HCO-H 2 folic acid) and the assay of (B) CCRF-CEM Aminoimidazole carboxamide ribotide transformylase (AICAR Tase) (⌬A 552 ) using 10-HCO-folic acid, (6R) 10-formyl-5,6,7,8 tetrahydrofolic acid (10-HCO-H 4 folic acid) and 10-HCO-H 2 folic acid. All points represent means Ϯ SD, n ϭ 4. A decrease in A 340 and A 552 indicates that the folate tested has activity in the dihydrofolate reductase and the AICAR Tase catalyzed reactions, respectively. Significant differences in the activities with each folate are discussed in the Results section.
10-HCO-H 2 folic acid was reported to be inactive with mammalian dihydrofolate reductase ). This previous report used dihydrofolic acid, which is known to be much more active than folic acid for mammalian dihydrofolate reductase (Coward et al. 1974) , as a positive control. Also, relatively short incubation times (i.e., 4 min) were used. Using folic acid as a positive control, and the longer incubation times, substantially increased the sensitivity of our dihydrofolate reductase assay.
There is no question that relatively long-term feeding of 10-HCO-folic acid does produce bioactive folates, which supports the growth of chickens (Gregory et al. 1984) and produces a relatively weak hematological response in humans (Spies et al. 1948) . Also, ϳ15% of an oral dose of radiolabeled 10-HCO-folic acid is retained and metabolized to tetrahydro compounds in rats in 24 h (Gregory et al. 1984) . In light of our failure to demonstrate bioactivity of 10-HCO-folic acid in a bacteria-free environment, a logical explanation for its bioactivity in chickens and humans and metabolism in rats would be that endogenous bacteria metabolized 10-HCO-folic acid to a form that is bioactive for vertebrates. A logical metabolic pathway for bacteria involves the dihydrofolate reductase catalyzed reduction of 10-HCO-folic acid to 10-HCO-H 4 folic acid. Remarkably, bacterial dihydrofolate reductase (in dramatic contrast to mammalian dihydrofolate reductase) is much more active with 10-HCO-folic acid than with folic acid (Dann et al. 1976; McIntyre and Harding 1977; Whitburn et al. 1983 ). The 10-HCO-H 4 folic acid produced by the bacteria would then be bioactive for the host. For example, S. faecalis (now E. hirae) is a very common bacteria of the human bowel and found in relatively high amounts in feces (Noble 1978) . 10-HCO-folic acid supports the growth of this bacteria . The metabolism of 10-HCO-folic acid in rats after 24 h (Gregory et al. 1984) might be explained by the 5-h mouth-to-cecum transit time in these animals (Perry et al. 1993) . Thus, in 5 h, any unabsorbed 10-HCO-folic acid would be available to the enteric bacteria of the rat.
In conclusion, 10-HCO-H 2 folic acid should be considered a bioactive folate for human leukemia cells because it substantially reversed MTX-induced growth suppression, and it served as a substrate for folate metabolizing enzymes. On the other hand, 10-HCO-folic acid had little or no effect in reversing MTX-induced growth suppression in this cell line. Its bioactivity is, therefore, quite low, and the metabolism (if any) of this folate by mammalian cells remains unclear. We propose that 10-HCO-folic acid be classified as a conditionally bioactive folate for vertebrates. Thus, 10-HCO-folic acid requires enteric bacteria to metabolize it to a bioactive form(s), which then can be utilized by the host.
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